Product name | Trial number | Phase | Condition | Start date |
---|---|---|---|---|
Lipo-MERIT | NCT02410733 | I | Melanoma | 03/2015 |
VAL-506440 | NCT03076385 | I | Influenza | 12/2015 |
VAL-339851 | NCT03345043 | I | Influenza | 05/2016 |
IVAC_W_bre1_uID | NCT02316457 | I | TNBC | 10/2016 |
mRNA-1325 | NCT03014089 | I | zika virus | 12/2016 |
mRNA-4157 | NCT03313778 | I | Solid tumors | 08/2017 |
mRNA-2416 | NCT03323398 | I/II | Relapsed/refractory solid tumor malignancies or lymphoma/ovarian cancer | 08/2017 |
CTX001 | NCT03655678 | III | TDT | 09/2018 |
Rabipur® | NCT03713086 | I | Rabies | 10/2018 |
mRNA-2752 | NCT03739931 | I | Relapsed/refractory solid tumor malignancies or lymphoma | 11/2018 |
mRNA-4157 | NCT03897881 | IIb | Stage III/IV melanoma | 07/2019 |
PCV | NCT03908671 | I | Esophageal cancer/non-small cell lung cancer | 10/2019 |
PCV | NCT04161755 | I | Pancreatic cancer | 12/2019 |
mRNA-1273 | NCT04283461 | I | COVID-19 | 03/2020 |
NR | NCT04426669 | I/II | GI cancer | 05/2020 |
ARCT-810 | NCT04416126 | I | OTCD | 06/2020 |
ARCT-021 | NCT04480957 | I/II | COVID-19 | 08/2020 |
NTLA-2001 | NCT04601051 | I | TTR-FAP/TTR-CM/wild-type transthyretin cardiac amyloidosis | 11/2020 |
ARCT-810 | NCT04442347 | I | OTCD | 11/2020 |
1 µg CoV2 SAM (LNP) | NCT04758962 | I | Virus diseases | 02/2021 |
mRNA-1273 | NCT04785144 | I | COVID-19 | 03/2021 |
Moderna COVID-19 Vaccine | NCT04811664 | III | COVID-19 | 03/2021 |
BNT162b2 | NCT04824638 | II | COVID-19 | 03/2021 |
ChAdV68-S | NCT04776317 | I | COVID-19 | 03/2021 |
mRNA-1273 | NCT04805125 | III | COVID-19 | 04/2021 |
BNT162b2/mRNA-1273 | NCT04900467 | NR | COVID-19 | 05/2021 |
NR | NCT05171959 | NR | COVID-19 | 05/2021 |
mRNA-1273 SARS-CoV-2 vaccine | NCT04894435 | II | COVID-19 | 05/2021 |
ChulaCov19 vaccine | NCT04566276 | I/II | COVID-19 | 05/2021 |
mRNA-1893 | NCT04917861 | II | Zika Virus | 06/2021 |
SARS-CoV-2 mRNA vaccine | NCT04847102 | III | COVID-19 | 07/2021 |
mRNA-1647 | NCT05085366 | III | CMV | 10/2021 |
Amaretto | NCT04981691 | I | Refractory malignant solid neoplasm | 10/2021 |
BNT162b2 | NCT04961229 | IV | COVID-19 | 10/2021 |
mRNA-1345 | NCT05127434 | II/III | RSV-LRTD | 11/2021 |
LNP-nCOV saRNA-02 Vaccine | NCT04934111 | I | COVID-19 | 12/2021 |
BNT162b2 | NCT05124171 | III | COVID-19 | 12/2021 |
Moderna mRNA-1273 | NCT05168813 | II/III | HIV/COVID-19 | 12/2021 |
NTLA-2002 | NCT05120830 | I/II | HAE | 12/2021 |
mRNA-1189 | NCT05164094 | I | EBV | 12/2021 |
BNT141 | NCT04683939 | I/IIa | Multiple solid tumors | 01/2022 |
WU-CART-007 | NCT04984356 | I/II | T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma | 01/2022 |
mRNA -1574 | NCT05217641 | I | HIV | 02/2022 |
AS03 | NCT05289037 | II | COVID-19 | 03/2022 |
mRNA-1273 | NCT05315362 | II | COVID-19 | 05/2022 |
mRNA-1644 | NCT05414786 | I | AIDS | 05/2022 |
mRNA-3745 | NCT05095727 | I/II | GSD | 06/2022 |
mRNA-1010 | NCT05415462 | III | Seasonal influenza | 06/2022 |
ARCT-810 | NCT05526066 | II | OTCD | 07/2022 |
mRNA -1215 | NCT05398796 | I | Nipah virus | 07/2022 |
BEAM-101 | NCT05456880 | I/II | SCD | 08/2022 |
OTX-2002 | NCT05497453 | I/II | HCC/solid tumor | 08/2022 |
mRNA-1468 | NCT05701800 | I/II | Herpes zoster | 01/2023 |
LVRNA009 | NCT05682638 | III | COVID-19 | 01/2023 |
ARCT-032 | NCT05712538 | I | CF | 02/2023 |
PTX-COVID19-B | NCT05534035 | III | COVID-19 | 02/2023 |
PTX-COVID19-B | NCT05534048 | III | COVID-19 | 02/2023 |
HBV vaccine | NCT05738447 | I | Liver cancer/ HCC | 02/2023 |
mRNA-1345/mRNA-1365 | NCT05743881 | I | RSV/HMPV | 02/2023 |
LVRNA010 | NCT05599802 | I | COVID-19 | 02/2023 |
NR | NCT05745545 | NR | COVID-19 | 02/2023 |
GLB-COV2-043 | NCT05602961 | I/II | COVID-19 | 02/2023 |
Moderna/Novavax | NCT05658523 | III | COVID-19 | 02/2023 |
mRNA-1011.1/mRNA-1011.2/mRNA-1012.1 | NCT05827068 | I/II | Seasonal influenza | 03/2023 |
JCXH-221 | NCT05743335 | I/II | COVID-19 | 03/2023 |
RVM-V001/RVM-V002 | NCT05788185 | I/II | COVID-19 | 03/2023 |
LVRNA021 | NCT05812014 | III | COVID-19 | 03/2023 |
mRNA-1283.222 | NCT05815498 | III | COVID-19 | 03/2023 |
Novavax | NCT05875701 | III | COVID-19 | 03/2023 |
mRNA-1083 | NCT05827926 | I/II | COVID-19/influenza | 04/2023 |
H3 mRNA / LNP Vaccine | NCT05829356 | I | Influenza | 04/2023 |
NR | NCT05761717 | NR | Hepatocellular carcinoma | 04/2023 |
mRNA-1195 | NCT05831111 | I | EBV | 04/2023 |
mRNA-1010 | NCT05827978 | III | Seasonal influenza | 04/2023 |
GSK4382276A | NCT05823974 | I/II | Influenza | 04/2023 |
H1ssF-3928 | NCT05755620 | I | Influenza | 04/2023 |
mRNA-1647 | NCT05683457 | II | CMV | 04/2023 |
LVRNA009 | NCT05428592 | III | COVID-19 | 04/2023 |
LVRNA012 | NCT05549206 | NR | COVID-19 | 04/2023 |
RQ3027/RQ3025 | NCT05907044 | NR | COVID-19 | 05/2023 |
BNT162b2/Sanofi | NCT05749926 | III | COVID-19 | 05/2023 |
SWIM816 | NCT05911087 | II/III | COVID-19 | 06/2023 |
RH109 | NCT05609045 | I | COVID-19 | 06/2023 |
mRNA-1010 | NCT05868382 | II | Influenza | 05/2023 |
TCR-T | NCT05905731 | I | Chronic hepatitis B | 06/2023 |
TI-0010 | NCT06205524 | I | COVID-19 | 07/2023 |
V3G CH848 Pr-NP1 60mcg | NCT05903339 | I | HIV | 08/2023 |
MT-302 (A) | NCT05969041 | I | Epithelial tumors, malignant | 08/2023 |
DCVC H1 HA mRNA vaccine | NCT05945485 | I | Influenza | 10/2023 |
RSV/hMPV mRNA LNP | NCT06237296 | I | RSV/HMPV | 01/2024 |
NR | NCT05387317 | III | COVID-19 | 04/2024 |